Immune Checkpoints Activators Competitive Landscape Technology And Pipeline Analysis

"Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018", report provides comprehensive Insight about pipeline drugs along with technologies involved across this mechanism. The report provides the detailed analysis of 80+ products along with 45+ companies involved. Memgen has been granted Orphan drug designation from US-FDA for ISF 35 for the treatment of stage IIb through IV melanoma.

Products covered by Phase

  • Phase II and Phase I
  • Pre-clinical and Discovery
  • Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Immune Checkpoints Activators

Pipeline analysis of 80+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Immune Checkpoints Activators

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.


Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.


Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope

  • The report provides competitive pipeline landscape of Immune Checkpoints Activators
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Immune Checkpoints Activators
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Establish a comprehensive understanding of the current pipeline scenario across Immune Checkpoints Activators to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Immune Checkpoints Activators R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Devise corrective measures for pipeline projects by understanding Immune Checkpoints Activators pipeline depth and focus of Indication therapeutics
  • Developing strategic initiatives to support your drug development activities
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Immune Checkpoints Activators to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
  • Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Immune Checkpoint Activators Overview

Rationale for targeting Immune checkpoint Agonist in oncology

Stimulatory checkpoint molecules

Advantages of Immune checkpoint Activators

Constraints of Immune Checkpoint Activators

Competitive Landscape

Collaborations and Deal values

Licensing Opportunities

Companies Investment Details for Future Development

Pipeline Therapeutics

Comparative Analysis

Mid Stage Products (Phase II)

Comparative Analysis

NKTR-214: Nektar Therapeutics

Product Description

Research and Development

Product Development Activities

(The list continues)

Early Stage Products (Phase I)

Comparative Analysis

Pre-clinical Stage Products

Comparative Analysis

Discovery Stage Products

Comparative Analysis

Therapeutic Assessment: Active Products

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Inactive Products

Comparative Analysis

Market Drivers and Barriers

Appendix

Table 1: Collaboration and Deal Values for Immune checkpoints Activators, 2017

Table 2: Licensing Opportunities

Table 3: Investment Details

Table 4: Total Products for Immune Checkpoint Activators

Table 5: Mid Stage Products (Phase II)

Table 6: Early Stage Products (Phase I)

Table 7: Pre-clinical Stage Products

Table 8: Discovery Stage Products

Table 9: Assessment by Monotherapy Products

Table 10: Assessment by Route of Administration

Table 11: Assessment by Stage and Route of Administration

Table 12: Assessment by Molecule Type

Table 13: Assessment by Stage and Molecule Type

Table 14: Dormant and Discontinued Products

Figure 1: Types of Immune Checkpoint receptors

Figure 2: Total Products for Immune Checkpoint Activators

Figure 3: Mid Stage Products (Phase II)

Figure 4: Early Stage Products (Phase I)

Figure 5: Pre-clinical Stage Products

Figure 6: Discovery Stage Products

Figure 7: Assessment by Monotherapy Products

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Dormant and Discontinued Products

AbbVie

Abeome Corporation

Ablynx

Aduro Biotech

Agenus

Alligator Bioscience AB

Alpine Immune Sciences

Amgen

AP Biosciences

Apexigen

Apogenix

BioInvent

Bristol-Myers Squibb

Celldex

Checkpoint Therapeutics

Crystal Bioscience

Daiichi Sankyo

DNAtrix

Enumeral

Eutilex

Five Prime Therapeutics

Genentech

Genmab

GlaxoSmithKline

Glenmark Pharmaceuticals

Janssen Biotech

JN Biosciences

Jounce Therapeutics

Leap Therapeutics

MedImmune

Memgen

Merck

Moderna Therapeutics

Nanjing Galaxy Biopharmaceutical

Nektar Therapeutics

Novartis

OncoMed Pharmaceuticals

Pelican Therapeutics

Pfizer

Pieris Pharmaceuticals

rEVO Biologics

Roche

Sanofi

Seattle Genetics

Sorrento Therapeutics

TheraMAB

  • Tags:
  • Immune Checkpoints Activators

Forward to Friend

Need A Quote